Immunoassay Detection of Human Beta-Defensins
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting and quantifying human β-defensins in bodily samples are hindered by masking agents, such as negatively charged moieties, which inhibit accurate detection and quantification.
Innovation Solution
An immunoassay method that reduces electrostatic interactions between β-defensin and negatively charged moieties in bodily samples using positively charged agents like CaCl2, allowing capture antibodies to bind β-defensin effectively, followed by detection with labeled antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional immunoassay methods are used to detect β-defensin, then the assay can proceed with standard protocols, but the detection accuracy is reduced due to masking by negatively charged moieties in bodily samples
Solution Approach 1:
The patent introduces a positively charged blocking agent as an intermediary substance that mediates between the negatively charged moieties in the sample and the β-defensin target. This blocking agent binds to the negatively charged moieties, preventing them from masking the β-defensin and interfering with antibody binding, thereby restoring detection accuracy without requiring modification of the immunoassay protocol
Solution Approach 2:
The patent changes the electrostatic parameter of the sample environment by adding positively charged blocking agents. This parameter change neutralizes the negative charge of masking moieties, reducing their ability to interact with and mask β-defensin, thereby improving measurement precision while maintaining standard assay conditions
2Measurement precision
If electrostatic interactions are not reduced, then the assay procedure remains simple, but the quantification of β-defensin is inaccurate due to binding inhibition
Solution Approach 1:
A positively charged blocking agent is introduced as an intermediary that simplifies the overall procedure by pre-neutralizing interfering moieties. This allows the immunoassay to proceed with standard antibody binding steps without requiring complex sample preparation or modification of the detection protocol
Solution Approach 2:
The blocking agent is added to the sample before the immunoassay begins, performing preliminary neutralization of negatively charged moieties. This preliminary action prevents masking during the subsequent antibody binding steps, ensuring accurate quantification while keeping the procedure straightforward
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables accurate detection and quantification of β-defensins in bodily samples by overcoming masking effects, providing sensitive and reproducible results for β-defensin levels in samples like saliva.
Implementation Method 1
The electrostatic interaction between β-defensin and negatively charged moieties in the bodily sample is reduced
Data Source
AI summary
A method of detecting β-defensin in a bodily sample from a subject includes reducing the electrostatic interaction between β-defensin and negatively charged moieties in the bodily sample prior to detecting the β-defensin with an antibody or epitope binding fragment thereof.